-🔥 Biteye AI Daily Report July 3

Today's zone market capitalization: $9.82B +8.98% The zone has rebounded strongly, closely linked to the overall market, and the innovation in the zone is gradually achieving results. 📈24h Coingecko Trading Volume Top 10: Token Trading Volume Market Capitalization Price Volatility 1- $VIRTUAL $274.1M $1.1B $1.62 +14.5% 2- $SAHARA $168.0M $164.0M $0.08 -2.7% 3- $KAITO $133.1M $392.5M $1.63 +2.7% 4- $TAO $131.5M $3.0B $335.21 +5.3% 5- $AI16Z $74.0M $179.1M $0.16 +18.1% 6- $BANANAS31 $67.3M $136.7M $0.01 +2.5% 7- $AIXBT $62.8M $127.7M $0.13 +11.2% 8- $PROMPT $53.0M $31.7M $0.14 +10.7% 9- $GOAT $38.9M $110.3M $0.11 +20.2% 10- $TUT $25.0M $49.1M $0.06 -3.8% ⭐️Key Information

• Mira @Mira_Network introduced how to enhance the reliability of AI outputs through a "consensus mechanism." Firstly, complex outputs are broken down into smaller, verifiable statements, each of which is independently verified by a distributed network. Subsequently, multiple models participate in the verification, and results are only recognized when all participants reach consensus. Additionally, the models participating in the verification must stake tokens and run real AI inferences, combining Proof of Work and Proof of Stake, ensuring fairness and credibility in the verification process. Comment: Mira achieves the goal of eliminating AI hallucinations through the clever design of a "consensus mechanism" between models.
• Bittensor subnet 68 @metanova_labs has released its operational data since launch: in 4 months, it has completed the screening of 4.6 million molecules, covering 7,000 protein targets, and explored a chemical library of over 1 billion compounds, making it one of the largest and most efficient decentralized drug screening practices known to date. METANOVA LABS is a biotechnology company based on cryptographic technology. Relying on the Bittensor network, its decentralized drug screening subnet integrates global computing resources and the collective wisdom of participants through the token $NOVA incentive mechanism, achieving a drug screening process without upfront computational costs. Comment: The immense potential of AI in the biopharmaceutical field has been confirmed. NOVA has achieved decentralized AI drug screening relying on Bittensor, marking a progress in AI drug development and enriching the application landscape of the Bittensor ecosystem.
• ASIMOV @ASIMOV_Protocol has launched the first phase product of ASIMOV, which is a multilingual development platform focused on trusted neuro-symbolic AI. Neuro-symbolic AI combines the advantages of neural networks and symbolic AI and provides cryptographic proof to ensure the clarity and trustworthiness of information sources. The platform supports converting any URL into a knowledge graph that can be utilized by large language models, while adopting a fully modular design that allows users to develop ASIMOV modules to access and leverage various specific data sources. Comment: As we mentioned before, knowledge graphs can improve the accuracy of AI output, and the launch of the ASIMOV platform takes it a step further, allowing AI to break free from the "black box" model, making the training and inference processes of the model more transparent, understandable, and auditable for humans. 📊 Data source: @xhunt_ai, Cookie DAO, Coingecko 💡Risk Warning: The above is for information sharing only and is not investment advice.